Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Recruiting now

Conditions studied: Endometrial Cancer

In brief

This study comprises 3 stages: 1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.

Key facts

Study ID

NCT06603506

Run by

Centre Francois Baclesse

People needed

16

Starts

2024-11-21

Expected to finish

2027-10-15

Last updated by the study team

2024-11-26

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patient aged 18 years or more
• Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
• Patient with localized endometrial cancer, presenting:
• A high-grade endometrioid histological type and/or
• P53 mutation and/or
• a non-endometrioid histological type regardless of P53 status.
• Patient affiliated to a social security scheme
• Information and signature of informed consent prior to any specific study procedure

You may not qualify if…

• Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
• Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.

Where it is running

• Centre François Baclesse — Caen, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.